A primary or metastatic malignant neoplasm involving the oral cavity. The majority are squamous cell carcinomas.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
Connect with organizations supporting the oral cavity cancer community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning oral cavity cancer
Updated Feb 6, 2026
Between 2011 and 2020, 410 new molecular entities were approved by the FDA, reflecting a 6.5% growth in the US. Globally, expedited approval programs have been crucial for anticancer drugs, with 9-75% receiving such designations in Europe, and China implementing similar pathways to enhance pharmaceutical development.
In 2024, the biotech sector has seen 47 M&A and IPO deals totaling $53 billion, with 15 exceeding $1 billion. Notably, cancer, rare diseases, and cell therapies are key areas attracting investment.
Novartis has cut six early-stage cancer candidates while adding two to refine its oncology strategy. CEO Vas Narasimhan emphasized ongoing investment in the early-stage pipeline and a focus on deals under $2 billion.
Pharma Times highlights the shift towards patient-centric oncology trials, emphasizing the use of data-driven insights to enhance cancer care. This approach aims to improve patient outcomes by integrating their experiences and preferences into trial designs.
Congress has passed a landmark bill aimed at protecting patient access to specialty pharmacies, crucial for managing complex health conditions such as cancer and rare diseases. This legislation is expected to stabilize the specialty pharmacy infrastructure, enhancing innovation and patient outcomes.